Gene Biotherapeutics Inc. (CRXM)

Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	64.93M
EPS (ttm)	0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	1.09
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CRXM

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebr...

• Industry: Biotechnology
• Founded: 2003
• CEO: Christopher Reinhard
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: CRXM

Full Company Profile

News

There is no news available yet.